XmAb20717
Phase 2Active 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Biliary Tract Cancer
Conditions
Biliary Tract Cancer
Trial Timeline
Apr 11, 2022 → Dec 2, 2026
NCT ID
NCT05297903About XmAb20717
XmAb20717 is a phase 2 stage product being developed by Xencor for Biliary Tract Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT05297903. Target conditions include Biliary Tract Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05297903 | Phase 2 | Active |
Competing Products
20 competing products in Biliary Tract Cancer